Related Experiment Videos
Management of bacterial meningitis
C A Hart1, L E Cuevas, O Marzouk
1Department of Medical Microbiology, University of Liverpool, UK.
The Journal of Antimicrobial Chemotherapy
|July 1, 1993
Summary
Bacterial meningitis poses a higher mortality risk in developing nations. While vaccines exist for some types, like Haemophilus influenzae (Hib) and meningococcal meningitis (Groups A and C), none are effective against Group B meningococcal infections, highlighting a critical prevention gap.
Area of Science:
- Infectious Diseases
- Microbiology
- Epidemiology
Background:
- Bacterial meningitis mortality is higher in developing countries (20-40%) compared to developed nations.
- Neurological deficits remain common (up to 25%) in survivors of bacterial meningitis, even with advanced antimicrobials.
- Neisseria meningitidis is a leading cause of bacterial meningitis globally, with epidemic strains and increasing Group B infections observed.
Purpose of the Study:
- To review the current landscape of bacterial meningitis, focusing on mortality, morbidity, and prevention strategies.
- To highlight the limitations of existing vaccines, particularly for young children and against specific strains like Group B meningococcus.
- To discuss the role of adjunctive therapies and the importance of preventative measures.
Main Methods:
- Literature review of bacterial meningitis epidemiology, treatment outcomes, and vaccine efficacy.
- Analysis of mortality and morbidity data across different geographical regions and causative agents.
- Evaluation of current prevention strategies, including chemoprophylaxis and immunoprophylaxis.
Main Results:
- Bacterial meningitis mortality varies significantly, with higher rates in developing countries.
- Neurological sequelae are a significant concern, persisting despite potent antimicrobial treatments.
- Effective vaccines exist for pneumococcal, Hib, and A/C meningococcal meningitis, but efficacy is limited in children under two. No vaccine is available for Group B meningococcal meningitis.
Conclusions:
- Prevention through vaccination and chemoprophylaxis is paramount for reducing bacterial meningitis burden.
- Development of broadly effective vaccines, especially against Group B meningococcus and for young children, is a critical unmet need.
- Adjunctive therapies like corticosteroids may offer benefits in specific meningitis types, but prevention remains the ultimate goal.